Back to Search
Start Over
Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
- Source :
-
Gynecologic oncology [Gynecol Oncol] 2024 Feb; Vol. 181, pp. 170-178. Date of Electronic Publication: 2024 Jan 12. - Publication Year :
- 2024
-
Abstract
- Germline and somatic genetic testing have become critical components of care for people with ovarian cancer. The identification of germline and somatic pathogenic variants as well as homologous recombination deficiency can contribute to the prediction of treatment response, prognostic outcome, and suitability for targeted agents (e.g. poly (ADP-ribose) polymerase (PARP) inhibitors). Furthermore, identifying germline pathogenic variants can prompt cascade genetic testing for at-risk relatives. Despite the clinical benefits and consensus recommendations from several organizations calling for universal genetic testing in ovarian cancer, only about one third of patients complete germline or somatic genetic testing. The members of the Society of Gynecologic Oncology (SGO) Clinical Practice Committee have composed this statement to provide an overview of germline and somatic genetic testing for patients with epithelial ovarian cancer, focusing on available testing modalities and options for care delivery.<br />Competing Interests: Declaration of Competing Interest Ms. Senter reports personal fees from AstraZeneca and GlaxoSmithKline, outside the submitted work. Dr. Urban reports personal fees from UpToDate, Inc., Access Hope, and Clinical Care Options, outside the submitted work. All other authors have nothing to disclose.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Female
Poly(ADP-ribose) Polymerase Inhibitors therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors pharmacology
Carcinoma, Ovarian Epithelial therapy
Carcinoma, Ovarian Epithelial drug therapy
Germ-Line Mutation
Genetic Testing
Poly(ADP-ribose) Polymerases genetics
Poly(ADP-ribose) Polymerases therapeutic use
Germ Cells pathology
BRCA1 Protein genetics
BRCA2 Protein genetics
Ovarian Neoplasms diagnosis
Ovarian Neoplasms genetics
Ovarian Neoplasms therapy
Antineoplastic Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1095-6859
- Volume :
- 181
- Database :
- MEDLINE
- Journal :
- Gynecologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38215513
- Full Text :
- https://doi.org/10.1016/j.ygyno.2023.12.010